Corvus director buys shares, receives option grant
Corvus Pharmaceuticals director David Scott Moore reported buying shares and receiving stock options.
Rhea-AI Filing Summary
Corvus Pharmaceuticals director David Scott Moore reported buying shares and receiving stock options. He completed an open-market purchase of 21,700 shares of Common Stock at an average price of $11.5316 per share, and now holds 21,700 common shares directly.
He was also granted a stock option for 15,000 shares of Common Stock at an exercise price of $11.60 per share. The option vests in full on the earlier of the first anniversary of the grant date or the date of Corvus Pharmaceuticals’ 2027 Annual Meeting of stockholders, assuming continuous service as a director until that vesting date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 21,700 shares
Net Buy
2 txns
Insider
Moore David Scott
Role
Director
Bought
21,700 shs ($250K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 15,000 | $0.00 | $0.00 |
| Purchase | Common Stock | 21,700 | $11.5316 | $250K |
Holdings After Transaction:
Stock Option (Right to Buy) — 15,000 contracts (Direct);
Common Stock — 21,700 shares (Direct)
Footnotes (1)
- F1. The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date.
Key Figures
Open-market purchase: 21,700 shares
Purchase price: $11.5316 per share
Shares held after purchase: 21,700 shares
+3 more
6 metrics
Open-market purchase
21,700 shares
Common Stock bought on June 11, 2026
Purchase price
$11.5316 per share
Average price for 21,700 Common Stock shares
Shares held after purchase
21,700 shares
Total direct Common Stock holdings post-transaction
Option grant size
15,000 options
Stock Option (Right to Buy) for Common Stock
Option exercise price
$11.60 per share
Conversion or exercise price for option grant
Option expiration
June 11, 2036
Expiration date of stock option grant
Key Terms
open-market purchase, Stock Option (Right to Buy, exercise price, vest and become exercisable, +1 more
5 terms
open-market purchase financial
"transaction_action": "open-market purchase""
An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price": "11.6000""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest and become exercisable financial
"shares subject to the option vest and become exercisable as to 100%"
Annual Meeting of the Issuer's stockholders financial
"date of the 2027 Annual Meeting of the Issuer's stockholders"
FAQ
What did Corvus Pharmaceuticals (CRVS) director David Scott Moore do in this Form 4?
David Scott Moore reported an open-market purchase of Corvus Pharmaceuticals Common Stock and a new stock option grant. The filing shows he bought shares directly and also received options tied to his continued board service.
What are the key terms of David Scott Moore’s Corvus Pharmaceuticals (CRVS) stock option grant?
He received a stock option for 15,000 shares of Corvus Pharmaceuticals Common Stock with an exercise price of $11.60 per share. The option expires on June 11, 2036, providing a long-dated right to buy shares at that price.
When do David Scott Moore’s Corvus Pharmaceuticals (CRVS) options vest?
The 15,000-share stock option vests 100% on the earlier of the first anniversary of the grant date or the date of Corvus Pharmaceuticals’ 2027 Annual Meeting, assuming he continues serving as a director through that vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
